Understand the source comparison
Peptides for Hashimoto's Thyroid Protocol Evidence Guide: Comparison Table
Thymalin Restores CD4+CD25+Foxp3+ T-regulatory cell differentiation from thymic progenitors Sechenov trial: 38% anti-TPO reduction at 12 weeks in 84 patients with active Hashimoto's 10mg IM daily × 10 days, then 10mg IM twice weekly × 12 weeks 22–38% mean redu
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Thymalin
- Restores CD4+CD25+Foxp3+ T-regulatory cell differentiation from thymic progenitors
- Sechenov trial: 38% anti-TPO reduction at 12 weeks in 84 patients with active Hashimoto's
- 10mg IM daily × 10 days, then 10mg IM twice weekly × 12 weeks
- 22–38% mean reduction; 41% of patients achieved <100 IU/mL threshold
- Strongest evidence base; requires IM administration; response best in disease duration <5 years
- Thymulin
- Zinc-dependent nonapeptide that enhances thymic output of mature regulatory T-cells
- 2020 Clinical Immunology study: 22% anti-TPO reduction at 8 weeks with selenium co-administration
- 50–100mcg SC 3× weekly × 8 weeks + zinc supplementation (15–30mg daily)
- 18–27% mean reduction; sustained at 24 weeks with monthly maintenance
- Requires zinc repletion; easier SC administration; lower peak antibody reduction than Thymalin
- Epithalon
- Telomerase activator with indirect immune-modulatory effects through cellular senescence reduction
- Observational data only; no controlled trials in Hashimoto's specifically
- 10mg SC daily × 10 days per cycle; 2–4 cycles annually
- No validated data for anti-thyroid antibody reduction
- Mechanism plausible but unproven; avoid as monotherapy for active Hashimoto's